Treats hypertension. ANDA 217377, held by Twi Pharms. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 217377 (Diltiazem Hydrochloride), held by Twi Pharms, was first approved by FDA on Mar 1, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules (Twice-a-Day Dosage) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medications, such as diuretics.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 1, 2023 | Original application | Approved | None posted |
| Diltiazem Hydrochloride60MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride90MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters